Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) noticed a major decline briefly curiosity throughout the month of December. As of December fifteenth, there was brief curiosity totalling 194,300 shares, a decline of 17.8% from the November thirtieth whole of 236,400 shares. Based mostly on a median day by day buying and selling quantity, of 39,000 shares, the days-to-cover ratio is presently 5.0 days. Presently, 5.4% of the shares of the corporate are brief offered.
Insider Shopping for and Promoting at Greenwich LifeSciences
In different information, CEO Snehal Patel acquired 2,000 shares of Greenwich LifeSciences inventory in a transaction on Friday, December ninth. The inventory was purchased at a median value of $13.11 per share, for a complete transaction of $26,220.00. Following the completion of the acquisition, the chief govt officer now owns 2,724,886 shares within the firm, valued at $35,723,255.46. The acquisition was disclosed in a doc filed with the Securities & Change Fee, which is accessible via this link. Over the past quarter, insiders purchased 13,500 shares of firm inventory price $145,510. 52.14% of the inventory is owned by insiders.
Institutional Traders Weigh In On Greenwich LifeSciences
A number of massive traders have just lately modified their holdings of the inventory. Pura Vida Investments LLC bought a brand new stake in shares of Greenwich LifeSciences throughout the third quarter price roughly $179,000. Walleye Capital LLC acquired a brand new place in Greenwich LifeSciences throughout the second quarter price $90,000. Goldman Sachs Group Inc. acquired a brand new place in Greenwich LifeSciences throughout the second quarter price $104,000. Occudo Quantitative Methods LP acquired a brand new place in Greenwich LifeSciences throughout the second quarter price $199,000. Lastly, Cubist Systematic Methods LLC acquired a brand new place in Greenwich LifeSciences throughout the second quarter price $130,000. Hedge funds and different institutional traders personal 6.18% of the corporate’s inventory.
Greenwich LifeSciences Inventory Efficiency
NASDAQ GLSI traded down $0.07 on Friday, reaching $15.20. The inventory had a buying and selling quantity of 52,065 shares, in comparison with its common quantity of 39,987. Greenwich LifeSciences has a 12-month low of $6.82 and a 12-month excessive of $26.27. The enterprise’s 50-day shifting common value is $12.07 and its 200 day shifting common value is $10.20. The inventory has a market cap of $194.86 million, a P/E ratio of -26.67 and a beta of 0.81.
Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) final launched its quarterly earnings outcomes on Monday, November 14th. The corporate reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.01. On common, sell-side analysts predict that Greenwich LifeSciences will submit -0.57 earnings per share for the present 12 months.
About Greenwich LifeSciences
Greenwich LifeSciences, Inc, a medical stage biopharmaceutical firm, focuses on the event of novel most cancers immunotherapies for breast most cancers and different HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has accomplished Section IIb medical trial to stop breast most cancers recurrences in sufferers who’ve beforehand undergone surgical procedure.
This instantaneous information alert was generated by narrative science know-how and monetary information from MarketBeat in an effort to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you think about Greenwich LifeSciences, you will need to hear this.
MarketBeat retains monitor of Wall Avenue’s top-rated and finest performing analysis analysts and the shares they suggest to their purchasers each day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Greenwich LifeSciences wasn’t on the listing.
Whereas Greenwich LifeSciences presently has a “maintain” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.